A study on a handful of people with suspected mild Alzheimer’s disease (AD) suggests that a device that sends continuous electrical impulses to specific “memory” regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with Parkinson’s disease and depression, may offer hope for at least some with AD, an intractable disease with no cure.

See the original article here:
Deep brain stimulation may hold promise for mild Alzheimer’s disease

Scientists have developed a peptide that protects dopamine-producing neurons, freezing neurodegeneration in its tracks in preclinical trials. This peptide could be easily delivered by daily injections or absorbed through the skin from an adhesive patch as a preventative therapy for Parkinson’s disease, she says.

Read More:
Freezing Parkinson’s in its tracks: Researcher developing therapy to halt symptoms in Parkinson’s patients

Scientists have developed a peptide that protects dopamine-producing neurons, freezing neurodegeneration in its tracks in preclinical trials. This peptide could be easily delivered by daily injections or absorbed through the skin from an adhesive patch as a preventative therapy for Parkinson’s disease, she says.

More:
Freezing Parkinson’s in its tracks

Researchers have succeeded in developing a biosynthetic polyphenol that improves cognitive function in mice with Alzheimer’s disease (AD). The findings provide insight in determining the feasibility of biosynthetic polyphenols as a possible therapy for AD in humans, a progressive neurodegenerative disease for which there is currently no cure.

Read the original post:
Biosynthetic grape-derived compound prevents progression of Alzheimer’s disease in animal model

Alzheimer’s disease (AD) is an incurable, progressive neurodegenerative disease affecting over five million people worldwide, and is the leading cause of dementia in the elderly. Currently, intravenous human immunoglobulin (IVIG) treatment is being explored in multiple off-label uses other than immunotherapy, including AD. Several clinical studies assessing the tolerability and efficacy of IVIG in Alzheimer’s disease subjects are in progress with inconsistent outcomes.

Read the article:
Intravenous vaccination promotes brain plasticity and prevents memory loss in Alzheimer’s disease